Altimmune (NASDAQ:ALT) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Altimmune's stock has been given a sell (D-) rating by Weiss Ratings, indicating a negative outlook from analysts.
• Several analysts have revised their target prices for Altimmune, with JMP Securities lowering it from $25.00 to $15.00, while UBS Group has adjusted theirs from $26.00 to $24.00.
• The company's stock recently traded up 0.6%, reaching a price of $3.99, with an average target price of $17.40 from analysts.

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Several other equities analysts also recently commented on the stock. JMP Securities lowered their target price on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a research report on Thursday, July 10th. UBS Group lowered their target price on shares of Altimmune from $26.00 to $24.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. William Blair reissued a "market perform" rating on shares of Altimmune in a research report on Friday, June 27th. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Monday. Finally, Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $17.40.

Altimmune Stock Up 0.6%

Shares of NASDAQ ALT traded up $0.03 during mid-day trading on Friday, reaching $3.99. The company had a trading volume of 1,386,540 shares, compared to its average volume of 3,524,037. Altimmune has a twelve month low of $2.90 and a twelve month high of $11.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. The stock has a market capitalization of $351.72 million, a PE ratio of -3.38 and a beta of 0.07. The stock's 50 day moving average is $3.79 and its 200-day moving average is $4.56.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently made changes to their positions in ALT. GAMMA Investing LLC lifted its stake in shares of Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock valued at $34,000 after buying an additional 4,598 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company's stock valued at $39,000 after acquiring an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in shares of Altimmune in the second quarter valued at approximately $40,000. Prudential Financial Inc. acquired a new stake in shares of Altimmune in the second quarter valued at approximately $43,000. Finally, Headland Capital LLC acquired a new stake in shares of Altimmune in the first quarter valued at approximately $50,000. Institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.